COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 14 FDA records to the applicant name Abbott. The collection includes 2 510(k) clearances. It includes 1 original PMA approval. 4 entries are PMA supplements. 7 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 6, 2019 to Oct 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code DSQ appears in 12 of the 14 linked filings. The collection spans 2 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P170038, with 12 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 6035 Stoneridge Dr., Pleasanton, CA, 94588. Recorded on P170038/S034, decision dated Oct 30, 2026.
Device categories in this collection
Ventricular (Assist) Bypass; Catheter, Percutaneous.
Changes described in PMA records
FDA posted a 30-day notice for supplement S034 to PMA P170038 for the CentriMag Circulatory Support System. The stated decision scope is a manufacturing process change to the routine bioburden monitoring program for the CentriMag Blood Pump. The supplement type is listed as Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the decision is recorded as OK30.
This notice does not represent a new approval of the entire system or a change in indication. The source statement identifies only the bioburden monitoring program change; it does not describe the specific monitoring method, acceptance criteria, or manufacturing site affected. No safety or effectiveness conclusion is provided in the source fields.
FDA approval-order wording
a manufacturing process change to the routine bioburden monitoring program for the CentriMag Blood Pump
Oct 30, 2026 · 30-Day NoticeThe FDA database entry P170038/S033 records a 30-day notice for Abbott's CentriMag Circulatory Support System, classified under product code DSQ for ventricular assist bypass in cardiovascular devices. The reported change is the addition of "an additional second-tier supplier of the CentriMag Motor Protection Cup component," with the supplement reason labeled as a process change covering manufacturer, sterilizer, packager, or supplier. This describes a supply-chain arrangement for one named component, not a modification to the device's approved design or labeling.
Because S033 is a supplement to PMA P170038, it sits within that original approval rather than constituting a new approval of the CentriMag system as a whole. The source statement gives the component and the supplier tier but does not name the supplier, describe qualification testing, or present data bearing on safety or clinical effectiveness; the notice's purpose is regulatory reporting of the change, and should not be read as independent confirmation of either.
FDA approval-order wording
an additional second-tier supplier of the CentriMag Motor Protection Cup component
Oct 2, 2026 · 30-Day NoticeThe FDA record for P170038/S032 describes a 30-day notice under the CentriMag Circulatory Support System PMA, with the stated purpose of replacing existing wave soldering equipment with new wave soldering equipment. The listed supplement reason is a process change involving a manufacturer, sterilizer, packager, or supplier. The device category is ventricular (assist) bypass, specialty cardiovascular, product code DSQ, applicant Abbott.
The identifier establishes this as a supplement to PMA P170038 rather than a new approval of the whole system, and it is a manufacturing notice rather than an original PMA. The statement does not name the affected facility, equipment model, process controls, or validation data, and it does not say whether soldering affects a patient-contacting component. The reported purpose is not evidence of safety or clinical effectiveness, and the record gives no basis for a new indication or clinical use.
FDA approval-order wording
replacement of the existing wave soldering equipment with new wave soldering equipment
Sep 2, 2026 · 30-Day NoticeFDA’s recorded scope: A manufacturing change to implement a new Printed Circuit Board Assembly (PCBA) Test System for the Mag Monitor.
May 5, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for a modification to the electromagnetic compatibility (EMC) coating on the Mag Monitor housing
May 4, 2026 · Real-Time ProcessSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.